Nav: Home

IV beta blockers before angioplasty are safe, but offer no clinical benefit

April 03, 2016

Giving intravenous beta blockers before performing a coronary angioplasty in patients who had experienced the deadliest form of heart attack--ST-segment elevation myocardial infarction (STEMI)--was safe but did not reduce heart attack severity or improve blood flow from the heart's main pumping chamber, according to research presented at the American College of Cardiology's 65th Annual Scientific Session.

"In patients with STEMI, beta blockers have been shown to improve survival, reduce the risk of another heart attack, reduce life-threatening arrhythmias and prevent enlargement of the heart," said Vincent Roolvink, M.D., of Isala Klinieken in Zwolle, Netherlands, and lead author of the study. "This was the first large, double-blind, randomized, placebo-controlled trial to assess whether giving intravenous beta blockers before these patients undergo angioplasty would further improve their outcomes. Unfortunately, we showed that it did not."

STEMI is a severe form of heart attack caused by prolonged blockage of blood supply in the heart. It requires immediate angioplasty, a non-surgical procedure in which a balloon is fed into the blood vessels through a catheter and inflated to open narrowed or blocked arteries, allowing blood to flow. A stent is often placed at the blockage site to keep the artery open. In the United States, about 250,000 people experience a STEMI every year.

Results from two previous trials had suggested that giving intravenous beta blockers to STEMI patients before they underwent angioplasty could reduce heart attack severity or improve blood flow from the left ventricle, the heart's main pumping chamber, but these trials had shortcomings, Roolvink said. One had a small enrollment and the other, while larger, was not blinded or placebo-controlled and enrolled only patients whose STEMIs involved the front wall of the left ventricle.

In the EARLY-BAMI (Effect of Early Beta-blocker Administration before primary PCI in patients with ST-elevation Myocardial Infarction) trial, which was conducted in the Netherlands and Spain, 683 patients (average age 62, 75 percent male) with acute STEMI symptoms of less than 12 hours duration were randomly assigned to receive the beta blocker metoprolol or a placebo before undergoing angioplasty. The primary endpoint was the severity of the heart attack as measured by magnetic resonance imaging (MRI) at 30 days. Secondary endpoints were levels of cardiac enzymes and number of occurrences of ventricular arrhythmia. Safety endpoints were symptoms of an abnormally slow heart rate, symptoms of abnormally low blood pressure and cardiogenic shock (sudden inability of the heart to pump enough blood to meet the body's needs).

At 30 days of follow up, the primary endpoint of average heart attack severity measured by MRI was 15.3 percent of left ventricular volume on average in the beta blockers group, compared with 14.9 percent in the placebo group, a difference that was not statistically significant, Roolvink said. Nor were there significant differences between the two groups on blood flow from the left ventricle or levels of cardiac enzymes (secondary endpoints). Ventricular arrhythmias occurred in 3.6 percent of patients who received beta blockers and in 6.9 percent of those who received a placebo, a difference that met the threshold for statistical significance but did not result in a clinically significant difference, Roolvink said. Sixteen patients in the beta blockers group experienced symptoms of an abnormally slow heart rate, symptoms of abnormally low blood pressure, or cardiogenic shock, compared with 21 patients in the placebo group, a difference that again was not statistically significant.

A limitation of the study is that overall heart attack severity among enrolled patients was lower than expected, which could explain why beta blocker treatment appeared to offer no benefit, Roolvink said. Also, although MRI analyses for the primary endpoint were blinded for both heart rate and study medication, it was not possible to blind physicians and nurses to patients' heart rate and blood pressure.

Going forward, researchers said additional large randomized trials are needed to clarify whether intravenous beta blocker treatment before angioplasty offers any benefit for STEMI patients.
-end-
The Early-BAMI trial was funded by the Dutch Heart Foundation and by an unrestricted grant from Medtronic, Inc.

The study was published in the Journal of the American College of Cardiology simultaneously with its presentation at the scientific session.

The ACC's Annual Scientific Session, which in 2016 will be April 2-4 in Chicago, brings together cardiologists and cardiovascular specialists from around the world to share the newest discoveries in treatment and prevention. Follow @ACCMediaCenter and #ACC16 for the latest news from the meeting.

The American College of Cardiology is a 52,000-member medical society that is the professional home for the entire cardiovascular care team. The mission of the College is to transform cardiovascular care and to improve heart health. The ACC leads in the formation of health policy, standards and guidelines. The College operates national registries to measure and improve care, offers cardiovascular accreditation to hospitals and institutions, provides professional medical education, disseminates cardiovascular research and bestows credentials upon cardiovascular specialists who meet stringent qualifications.

Roolvink will be available to the media in a press conference on Sunday, April 3, 2016, at 12:15 p.m. CT/1:15 p.m. ET/5:15 p.m. UTC in Room N229.

Roolvink will present the study, "Effect Of Early Administration Of Intravenous Beta Blockers In Patients With ST-Elevation Myocardial Infarction Before Primary Percutaneous Coronary Intervention. The Early-BAMI Trial" on Sunday, April 3, 2016, at 10:45 a.m. CT/11:45 a.m. ET/3:45 p.m. UTC in the Main Tent (North Hall B1).

American College of Cardiology

Related Blood Pressure Articles:

Brain blood flow sensor discovery could aid treatments for high blood pressure & dementia
A study led by researchers at UCL has discovered the mechanism that allows the brain to monitor its own blood supply, a finding in rats which may help to find new treatments for human conditions including hypertension (high blood pressure) and dementia.
Here's something that will raise your blood pressure
The apelin receptor (APJ) has been presumed to play an important role in the contraction of blood vessels involved in blood pressure regulation.
New strategy for treating high blood pressure
The key to treating blood pressure might lie in people who are 'resistant' to developing high blood pressure even when they eat high salt diets, shows new research published today in Experimental Physiology.
Arm cuff blood pressure measurements may fall short for predicting heart disease risk in some people with resistant high blood pressure
A measurement of central blood pressure in people with difficult-to-treat high blood pressure could help reduce risk of heart disease better than traditional arm cuff readings for some patients, according to preliminary research presented at the American Heart Association's Hypertension 2019 Scientific Sessions.
Heating pads may lower blood pressure in people with high blood pressure when lying down
In people with supine hypertension due to autonomic failure, a condition that increases blood pressure when lying down, overnight heat therapy significantly decreased systolic blood pressure compared to a placebo.
The Lancet Neurology: High blood pressure and rising blood pressure between ages 36-53 are associated with smaller brain volume and white matter lesions in later years
A study of the world's oldest, continuously-studied birth cohort tracked blood pressure from early adulthood through to late life and explored its influence on brain pathologies detected using brain scanning in their early 70s.
Blood pressure control is beneficial, is it not?
Until recently, physicians had generally assumed that older adults benefit from keeping their blood pressure below 140/90 mmHg.
The 'blue' in blueberries can help lower blood pressure
A new study published in the Journal of Gerontology Series A has found that eating 200g of blueberries every day for a month can lead to an improvement in blood vessel function and a decrease in systolic blood pressure in healthy people.
How to classify high blood pressure in pregnancy?
The American Heart Association (AHA) and the American College of Cardiology (ACC) changed their guidance to lower the threshold criteria for hypertension in adults.
Discovery could advance blood pressure treatments
A team of Vanderbilt University Medical Center researchers, working with the US Department of Veteran's Affairs (VA), has discovered genetic associations with blood pressure that could guide future treatments for patients with hypertension.
More Blood Pressure News and Blood Pressure Current Events

Trending Science News

Current Coronavirus (COVID-19) News

Top Science Podcasts

We have hand picked the top science podcasts of 2020.
Now Playing: TED Radio Hour

Teaching For Better Humans 2.0
More than test scores or good grades–what do kids need for the future? This hour, TED speakers explore how to help children grow into better humans, both during and after this time of crisis. Guests include educators Richard Culatta and Liz Kleinrock, psychologist Thomas Curran, and writer Jacqueline Woodson.
Now Playing: Science for the People

#556 The Power of Friendship
It's 2020 and times are tough. Maybe some of us are learning about social distancing the hard way. Maybe we just are all a little anxious. No matter what, we could probably use a friend. But what is a friend, exactly? And why do we need them so much? This week host Bethany Brookshire speaks with Lydia Denworth, author of the new book "Friendship: The Evolution, Biology, and Extraordinary Power of Life's Fundamental Bond". This episode is hosted by Bethany Brookshire, science writer from Science News.
Now Playing: Radiolab

Dispatch 3: Shared Immunity
More than a million people have caught Covid-19, and tens of thousands have died. But thousands more have survived and recovered. A week or so ago (aka, what feels like ten years in corona time) producer Molly Webster learned that many of those survivors possess a kind of superpower: antibodies trained to fight the virus. Not only that, they might be able to pass this power on to the people who are sick with corona, and still in the fight. Today we have the story of an experimental treatment that's popping up all over the country: convalescent plasma transfusion, a century-old procedure that some say may become one of our best weapons against this devastating, new disease.   If you have recovered from Covid-19 and want to donate plasma, national and local donation registries are gearing up to collect blood.  To sign up with the American Red Cross, a national organization that works in local communities, head here.  To find out more about the The National COVID-19 Convalescent Plasma Project, which we spoke about in our episode, including information on clinical trials or plasma donation projects in your community, go here.  And if you are in the greater New York City area, and want to donate convalescent plasma, head over to the New York Blood Center to sign up. Or, register with specific NYC hospitals here.   If you are sick with Covid-19, and are interested in participating in a clinical trial, or are looking for a plasma donor match, check in with your local hospital, university, or blood center for more; you can also find more information on trials at The National COVID-19 Convalescent Plasma Project. And lastly, Tatiana Prowell's tweet that tipped us off is here. This episode was reported by Molly Webster and produced by Pat Walters. Special thanks to Drs. Evan Bloch and Tim Byun, as well as the Albert Einstein College of Medicine.  Support Radiolab today at Radiolab.org/donate.